Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, signaling an updated version of the page rendering. This does not reflect changes to the study details or content.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.5.4 was added and Revision: v3.5.3 was removed, indicating a software version update on the page. The underlying study content and navigation remain unchanged.SummaryDifference0.1%

- Check36 days agoChange DetectedThe study record's revision label was updated from v3.5.2 to v3.5.3, indicating a new version of the entry. This update reflects a metadata revision rather than changes to the study content, eligibility, or results.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision from v3.4.3 to v3.5.0. There are no visible changes to the study details, outcomes, or eligibility criteria on the page.SummaryDifference0.1%

- Check86 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.